



### disclosure

I might talk about...


treatments that aren't available yet


treatments that might work but aren't proven

theoretical stuff that doesn't seem practical


## Where are you from?

When poll is active, respond at PollEv.com/darylwile627





### What's your connection to PD?




### What symptom bothers you the most?

Respond at PollEv.com/darylwile627 Text DARYLWILE627 to 22333 once to join, then text your message



### What treatment do you want to learn more about?


Respond at Pollev.com/darylwile627 Text DARYLWILE627 to 22333 once to join, then text your message







## Have you used cannabis for PD symptoms?



### If you have used cannabis for PD, what positive effects did it have?



### If you have used cannabis for PD, what negative effects did it have?



### What are cannabinoids used for in PD?



Good quality evidence	"Evidence"	Anecdotes
	+/- Dyskinesia +/- Tremor +/- Protective	Appetite/nausea Insomnia Pain Anxiety











# **Expected effect of Cannabinoids 'Opinion' of 56 Movement Disorder Specialists**



### What are the risks?



## What are you smoking? (Part 2)



Forensic Science International Volume 294, January 2019, Pages e25-e27



Short Communication

The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids

Justin L. Poklis  $^2$   $^2$   $^2$  , Haley A. Mulder  $^b$ , Michelle R. Peace  $^b$ 

Table 1

Table 1

Detection of CBD and other psychoactive compounds in CBD e-liquids.

Sample (Received for Analysis)	CBD	THC	5F-ADB	DXM
Liquid Gold Strawberry	Х		Х	
Diamond CBD Vape Additive	Х		Х	
Samples (Purchased)	CBD	THC	5F-ADB	DXM
Liquid Gold Strawberry	Х		X	
Liquid Gold Jungle Juice	X	X	X	
Diamond CBD Vape Additive	X			X
Blue CBD 250 mg	X			
Blue CBD 1000 mg	X			
Diamond CBD 50 mg	X			
Diamond CBD 1000 mg	X	X		

X-indicates detection.



### The risk of contaminants and false labeling in the exploding CBD industry





"Comparing this to other supplements that we've tested, we found really high levels of pesticides, really high levels of heavy metals," Callan said.



The lab tested the top-selling 240 products for 300 contaminants and for truth in labeling.

Was the amount of CBD claimed actually in the product?


After thousands of tests, 70 percent of products were found "highly contaminated" with heavy metals like lead and arsenic, herbicides like glyphosate (the active ingredient in RoundUp) and a host of other contaminants including pesticides, BPA and toxic mold.


One product - by Ananda Hemp - contained levels of lead so high, it exceeded by 100-times what the EPA would consider actionable for drinking water.


More than half the products tested had labels that inaccurately reflected the concentration of CBD in the product.


"There were several that claimed to have CBD on the label where we found no CBD whatsoever," Callan said. "All the way up to, on the other end of the spectrum, there are products that have five, six times as much CBD in them as they say they do."
















## Radical Parkinson's treatment tested in patients

By Alex Therrien Health reporter, BBC News

① 27 February 2019













## Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease


Alan Whone, Matthias Luz, Mihaela Boca, Max Woolley, Lucy Mooney, Sonali Dharia, Jack Broadfoot, David Cronin, Christian Schroers, Neil U Barua Lara Longpre, C Lynn Barclay, Chris Boiko, Greg A Johnson, H Christian Fibiger, Rob Harrison, Owen Lewis, Gemma Pritchard, Mike Howell, Charlie Irving, David Johnson, Suk Kinch, Christopher Marshall, Andrew D Lawrence, Stephan Blinder, Vesna Sossi, A Jon Stoessl, Paul Skinner, Erich Mohr, Steven S Gill

Brain, Volume 142, Issue 3, March 2019, Pages 512–525, https://doi.org/10.1093/brain/awz023


Published: 26 February 2019 Article history ▼

### **Robot surgery implanted brain port**

Infusion of growth factor into brain targeting areas important to PD (GDNF)




Transcutaneous port with mounted 4-line drug application set with in-line bacteria, air and particle filters





Patient receiving infusion





Skull-mounted port



Gadolinium test infusion


GDNF study Infusion suite







## **Apomorphine**



In Canada as MOVAPO

Not available in Canada

## Kynmobi

FDA Declines to Approve APL-130277 for Treating 'Off' Periods; More Information Requested







### **CADTH submission**

Call for patient input posted	January 25, 2019
Patient group input closed	March 18, 2019
Clarification:	
- Patient input submission received from the David Phinney	Foundation for Parkinson's
Parkinson Association of Alberta, Parkinson Canada, Parkin	son Society BC and The
Michael J. Fox Foundation for Parkinson's Research	
Patient input summary sent for review to patient input	March 27, 2019
groups	Walcii 27, 2019
Patient group comments on input summary closed	April 02, 2019
Clarification:	
- Patient input summary feedback received	
Submission received	February 25, 2019
Submission accepted for review	March 11, 2019
Review initiated	March 12, 2019
Draft CADTH review report(s) sent to applicant	May 27, 2019
Comments from applicant on draft CADTH review report(s) received	June 05, 2019
Redaction requests from applicant on draft CADTH review	June 12, 2019
report(s) received	

### **Not currently available in Canada**







### Alpha-synuclein

support study design.

This protein forms toxic clumps in some brain and body cells of people with PD.

#### BIIB054

Biogen's antibody aims to prevent aggregated alpha-synuclein from spreading. MJFF is funding tool development and data collection that



#### **NPT088**

Proclara's (previously Neurophage) drug candidate aims to prevent alphasynuclein from clumping together. MJFF funded pre-clinical work.



View Grant >

#### PD01A

AFFiRiS' vaccine aims to stimulate antibodies against alpha-synuclein. MJFF funded pre-clinical work, a portion of the Phase I trial and boost studies.



View Grant >

### RO7046015

Prothena/Roche's antibody aims to prevent aggregated alpha-synuclein from spreading. MJFF is funding tool development and data collection that support study design.



#### ─ GBA

Mutations in the GBA gene are associated with Parkinson's disease and are linked to certain cellular dysfunction.

#### GZ/SAR402671

that support study design.

Sanofi Genzyme's drug reduces production of lipids that build up with GBA mutations. MJFF is funding tool development and data collection



LTI-291

Lysosomal Therapeutics' oral drug may offset dysfunction associated with GBA mutation. MJFF funded the pre-clinical work.



View Grant >

#### ─ LRRK2


Mutations in the LRRK2 gene are associated with Parkinson's disease and linked to greater activity of the LRRK2 protein.

#### DNL201

Denali's LRRK2 inhibitor aims to lower heightened LRRK2 activity. MJFF funded safety studies that supported the trial.











The fruit of your labor

Ongoing clinical research - thank you Diane and Eddie Aizen!

Coming soon... Expanded allied health services


> physical therapy speech pathology social work

for PD patients through the Okanagan Movement Disorder Clinic

Thanks to your fundraising efforts And the PSBC!

## **Meeting the needs**

Northern Health	494	(0.34)
Interior Health	2405	(0.52)
Island Health	2649	(0.56)
Vancouver Coastal	3067	(0.48)
Fraser Health	4480	(0.49)
British Columbia	13095	




### 2016-2017

### Movement disorder clinic progress

Year	Patient visits / month
2015	69
2016	124
2017	128
2018	112
2019	116

### **Long Term Planning**



KGH Foundation Brain Health Campaign (expected 2020)

Improve patient care for brain disorders

### What is on your wish list?



